MX350745B - El uso de un compuesto de carbamoilo para el tratamiento del sindrome de fibromialgia. - Google Patents

El uso de un compuesto de carbamoilo para el tratamiento del sindrome de fibromialgia.

Info

Publication number
MX350745B
MX350745B MX2012005257A MX2012005257A MX350745B MX 350745 B MX350745 B MX 350745B MX 2012005257 A MX2012005257 A MX 2012005257A MX 2012005257 A MX2012005257 A MX 2012005257A MX 350745 B MX350745 B MX 350745B
Authority
MX
Mexico
Prior art keywords
methods
fibromyalgia syndrome
treating fibromyalgia
treating
syndrome
Prior art date
Application number
MX2012005257A
Other languages
English (en)
Other versions
MX2012005257A (es
Inventor
Susan Marie Melnick
Sung James Lee
Original Assignee
Sk Biopharmaceuticals Co Ltd *
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sk Biopharmaceuticals Co Ltd * filed Critical Sk Biopharmaceuticals Co Ltd *
Publication of MX2012005257A publication Critical patent/MX2012005257A/es
Publication of MX350745B publication Critical patent/MX350745B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/223—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of alpha-aminoacids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychiatry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La invención está dirigida a un método de tratamiento del síndrome de fibromialgia en un sujeto, que comprende administrar una cantidad terapéuticamente eficaz de un compuesto de carbamoílo, o una sal farmacéuticamente aceptable del mismo.
MX2012005257A 2009-11-06 2010-11-01 El uso de un compuesto de carbamoilo para el tratamiento del sindrome de fibromialgia. MX350745B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25867209P 2009-11-06 2009-11-06
PCT/KR2010/007603 WO2011055944A2 (en) 2009-11-06 2010-11-01 Methods for treating fibromyalgia syndrome

Publications (2)

Publication Number Publication Date
MX2012005257A MX2012005257A (es) 2012-06-19
MX350745B true MX350745B (es) 2017-09-14

Family

ID=43970515

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012005257A MX350745B (es) 2009-11-06 2010-11-01 El uso de un compuesto de carbamoilo para el tratamiento del sindrome de fibromialgia.

Country Status (12)

Country Link
US (3) US8927602B2 (es)
EP (1) EP2496227B1 (es)
JP (1) JP5901528B2 (es)
KR (1) KR101783633B1 (es)
CN (1) CN102781436B (es)
AU (2) AU2010316172B2 (es)
BR (1) BR112012010648A2 (es)
CA (1) CA2779442A1 (es)
ES (1) ES2743153T3 (es)
MX (1) MX350745B (es)
RU (1) RU2557533C2 (es)
WO (1) WO2011055944A2 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101335941B1 (ko) 2005-06-08 2013-12-04 에스케이바이오팜 주식회사 수면-각성 장애의 치료
WO2011005473A2 (en) 2009-06-22 2011-01-13 Shionogi Pharma, Inc. Methods for treating or preventing fatigue
AU2010316106B2 (en) 2009-11-06 2015-10-22 Sk Biopharmaceuticals Co., Ltd. Methods for treating attention-deficit/hyperactivity disorder
MX350745B (es) * 2009-11-06 2017-09-14 Sk Biopharmaceuticals Co Ltd * El uso de un compuesto de carbamoilo para el tratamiento del sindrome de fibromialgia.
US9610274B2 (en) 2010-06-30 2017-04-04 Sk Biopharmaceuticals Co., Ltd. Methods for treating bipolar disorder
JP6530741B2 (ja) 2013-03-13 2019-06-12 エアリアル，バイオファーマ，エルエルシー カタプレキシーの治療
DK3021838T3 (da) 2013-07-18 2020-08-24 Jazz Pharmaceuticals Ireland Ltd Behandling af fedme
US10888542B2 (en) 2014-02-28 2021-01-12 Sk Biopharmaceuticals Co., Ltd. Aminocarbonylcarbamate compounds
TWI655179B (zh) 2014-02-28 2019-04-01 南韓商愛思開生物製藥股份有限公司 胺基羰基胺基甲酸酯化合物
KR102489052B1 (ko) * 2016-05-19 2023-01-16 에스케이바이오팜 주식회사 섬유근육통 또는 섬유근육통의 연관된 기능적 증후군을 예방 또는 치료하기 위한 카바메이트 화합물의 용도
KR102513800B1 (ko) 2016-09-06 2023-03-24 에스케이바이오팜 주식회사 (r)-2-아미노-3-페닐프로필 카바메이트의 용매화물 폼
US10195151B2 (en) * 2016-09-06 2019-02-05 Jazz Pharmaceuticals International Iii Limited Formulations of (R)-2-amino-3-phenylpropyl carbamate
KR102616545B1 (ko) * 2016-10-06 2023-12-26 재즈 파마슈티칼즈 아일랜드 리미티드 카바모일 페닐알라닌올 화합물 및 이의 용도
US11602547B2 (en) * 2017-03-10 2023-03-14 University Of Louisville Research Foundation, Inc. FasL-engineered biomaterials with immunomodulatory function
AU2018278332B2 (en) 2017-06-02 2022-05-19 Jazz Pharmaceuticals Ireland Limited Methods and compositions for treating excessive sleepiness
CA3071779A1 (en) 2017-07-31 2019-02-07 Jazz Pharmaceuticals Ireland Limited Carbamoyl phenylalaninol analogs and uses thereof
KR101972333B1 (ko) 2017-08-07 2019-04-25 김재일 섬유근육통 진단용 조성물, 그를 포함하는 마이크로어레이 및 키트
KR20220038344A (ko) * 2019-07-23 2022-03-28 아스텔라스 파마 글로벌 디벨롭먼트, 인크. 통증과 관련된 수면 장애를 치료하는 방법
US10940133B1 (en) 2020-03-19 2021-03-09 Jazz Pharmaceuticals Ireland Limited Methods of providing solriamfetol therapy to subjects with impaired renal function

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ314570A (en) 1993-06-10 2000-11-24 Lilly Co Eli Treatment of emesis using tetrahydrobenz[cd]indole-6-carboxamides
GB9406857D0 (en) 1994-04-07 1994-06-01 Sandoz Ltd Improvements in or relating to organic compounds
KR100197892B1 (ko) 1994-09-09 1999-06-15 남창우 신규한 페닐알킬아미노 카바메이트 화합물과 그의 제조방법
KR0173862B1 (ko) 1995-02-11 1999-04-01 조규향 O-카바모일-(d)-페닐알라닌올 화합물과 그의 약제학적으로 유용한 염 및 이들의 제조방법
US5756817C1 (en) 1995-02-11 2001-04-17 Sk Corp O-carbamoyl-phenylananinol compounds their pharmaceutically useful salts and process for preparing the same
IT1275903B1 (it) 1995-03-14 1997-10-24 Boehringer Ingelheim Italia Esteri e ammidi della 1,4-piperidina disostituita
KR0173863B1 (ko) 1995-04-10 1999-04-01 조규향 페닐에 치환체가 있는 o-카바모일-페닐알라닌올 화합물과 그의 약제학적으로 유용한 염 및 이들의 제조방법
ES2170878T3 (es) * 1996-10-10 2002-08-16 Sk Corp Compuestos de o-carbamoil-fenilalaninol y sus sales farmaceuticamente utiles.
WO1998017636A1 (en) 1996-10-22 1998-04-30 Ortho Pharmaceutical Corporation Phenylalaninol derivatives for the treatment of central nervous system disorders
TW402591B (en) 1997-07-11 2000-08-21 Janssen Pharmaceutica Nv Monocyclic benzamides of 3- or 4-substituted 4-(aminomethyl)-piperidine derivatives
HUP0101511A3 (en) 1998-04-28 2002-12-28 Dainippon Pharmaceutical Co 1-[(1-substituted-4-piperidinyl)methyl]-4-piperidine derivatives, process for producing the same, medicinal compositions containing the same and intermediates of these compounds
US20010029262A1 (en) 1998-06-29 2001-10-11 Sethi Kapil Dev Method of treatment or prophylaxis
TW518218B (en) 1999-05-27 2003-01-21 Merck Patent Gmbh Pharmaceutical compositions comprising 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoylbenzofuran-5-yl)piperazine or its physiologically acceptable salts for use in the treatment of sub-type anxiety disorders
US20010034320A1 (en) 2000-01-18 2001-10-25 Hans-Michael Brecht NK1-receptor antagonists for treating restless legs syndrome
ATE318812T1 (de) 2000-12-21 2006-03-15 Bristol Myers Squibb Co Thiazolyl-inhibitoren von tyrosinkinasen der tec- familie
BR0207673A (pt) 2001-02-27 2004-12-28 Ortho Mcneil Pharm Inc Compostos de carbamato para o uso no tratamento de dor
CZ20032299A3 (cs) 2001-02-27 2004-08-18 Ortho@Mcneilápharmaceuticalźáinc Léčivo pro prevenci nebo léčbu motorických poruch
CA2443108A1 (en) 2001-04-03 2002-10-17 Merck & Co. Inc. N-substituted nonaryl-heterocyclo amidyl nmda/nr2b antagonists
US20040204341A1 (en) 2001-06-12 2004-10-14 Christopher Allen Nr2b receptor antagonists for the treatment or prevention of migraines
US20040115263A1 (en) 2002-08-26 2004-06-17 Robertson David W. Use of bupropion for treating restless legs syndrome
CA2499494A1 (en) 2002-09-20 2004-04-01 Pfizer Inc. N-substituted piperidinyl-imidazopyridine compounds as 5-ht4 receptor modulators
EP1620435A1 (en) 2003-04-21 2006-02-01 Pfizer Inc. IMADAZOPYRIDINE COMPOUNDS HAVING 5-HT sb 4 /sb RECEPTOR AGONISTIC ACTIVITY AND 5-HT sb 3 /sb RECEPTOR ANTAGONISTIC ACTIVITY
AP2184A (en) 2003-09-03 2010-12-02 Pfizer Benzimidazolone compounds having 5-HT4 receptor agonistic activity.
US20050080268A1 (en) 2003-10-08 2005-04-14 Yong-Moon Choi Process of preparing O-carbamoyl compounds in the presence of active amine group
EP1548011A1 (en) 2003-12-23 2005-06-29 Neuro3D Benzo[1,4]diazepin-2-one derivatives as phosphodiesterase PDE2 inhibitors, preparation and therapeutic use thereof
WO2005092882A1 (en) 2004-03-01 2005-10-06 Pfizer Japan, Inc. 4-amino-5-halogeno-benzamide derivatives as 5-ht4 receptor agonists for the treatment of gastrointestinal, cns, neurological and cardiovascular disorders
MX2007005172A (es) * 2004-10-28 2007-06-22 Sk Corp Terapia adjunta para la depresion.
CN101189228A (zh) 2005-04-08 2008-05-28 辉瑞产品有限公司 用作i型甘氨酸转运抑制剂的二环[3.1.0]杂芳酰胺
US7598279B2 (en) 2005-04-22 2009-10-06 Sk Holdings Co., Ltd. Neurotherapeutic azole compounds
KR101335941B1 (ko) * 2005-06-08 2013-12-04 에스케이바이오팜 주식회사 수면-각성 장애의 치료
EP1893291B1 (en) 2005-06-22 2010-03-03 SK Holdings Co., Ltd. Treatment of sexual dysfunction
ATE538784T1 (de) 2005-07-26 2012-01-15 Sk Biopharmaceuticals Co Ltd Verfahren zur behandlung von substanzbedingten erkrankungen
EP1754476A1 (en) 2005-08-18 2007-02-21 Schwarz Pharma Ag Lacosamide (SPM 927) for treating myalgia, e.g. fibromyalgia
MX2009003926A (es) 2006-10-13 2009-06-26 Janssen Pharmaceutica Nv Composiciones de fenilalquilamino-carbamato.
JP2010506941A (ja) * 2006-10-17 2010-03-04 リセラ，インク． 甲状腺眼症の治療のための方法、組成物及び製剤
US8642772B2 (en) 2008-10-14 2014-02-04 Sk Biopharmaceuticals Co., Ltd. Piperidine compounds, pharmaceutical composition comprising the same and its use
WO2011005473A2 (en) * 2009-06-22 2011-01-13 Shionogi Pharma, Inc. Methods for treating or preventing fatigue
US8232315B2 (en) 2009-06-26 2012-07-31 Sk Biopharmaceuticals Co., Ltd. Methods for treating drug addiction and improving addiction-related behavior
MX350745B (es) 2009-11-06 2017-09-14 Sk Biopharmaceuticals Co Ltd * El uso de un compuesto de carbamoilo para el tratamiento del sindrome de fibromialgia.
AU2010316106B2 (en) 2009-11-06 2015-10-22 Sk Biopharmaceuticals Co., Ltd. Methods for treating attention-deficit/hyperactivity disorder
US8623913B2 (en) 2010-06-30 2014-01-07 Sk Biopharmaceuticals Co., Ltd. Methods for treating restless legs syndrome

Also Published As

Publication number Publication date
US20150011625A1 (en) 2015-01-08
US9688620B2 (en) 2017-06-27
CA2779442A1 (en) 2011-05-12
JP5901528B2 (ja) 2016-04-13
AU2016200765B2 (en) 2017-06-15
KR20120083518A (ko) 2012-07-25
JP2013510142A (ja) 2013-03-21
WO2011055944A2 (en) 2011-05-12
KR101783633B1 (ko) 2017-10-10
BR112012010648A2 (pt) 2020-12-01
US20170349541A1 (en) 2017-12-07
US8927602B2 (en) 2015-01-06
RU2012123154A (ru) 2013-12-27
WO2011055944A3 (en) 2011-11-03
EP2496227B1 (en) 2019-05-22
CN102781436A (zh) 2012-11-14
ES2743153T3 (es) 2020-02-18
EP2496227A2 (en) 2012-09-12
AU2010316172A1 (en) 2012-05-24
MX2012005257A (es) 2012-06-19
CN102781436B (zh) 2014-01-08
AU2010316172B2 (en) 2015-11-12
RU2557533C2 (ru) 2015-07-20
AU2016200765A1 (en) 2016-02-25
US20120252892A1 (en) 2012-10-04
EP2496227A4 (en) 2013-04-24

Similar Documents

Publication Publication Date Title
MX350745B (es) El uso de un compuesto de carbamoilo para el tratamiento del sindrome de fibromialgia.
EP2588099A4 (en) METHOD OF TREATING THE RESTLESS LEG SYNDROME
WO2011055965A3 (en) Methods for treating attention-deficit/hyperactivity disorder
MX360030B (es) Metodos para tratar el trastorno bipolar.
PH12015501108B1 (en) Treatment of pulmonary disease
EA201300860A1 (ru) Кристаллические трипептидные ингибиторы эпоксикетон-протеазы
MX2013007336A (es) Compuestos de bi-heteroarilo como inhibidores de vps34.
MY179607A (en) Combinations of akt inhibitor compounds and abiraterone, and methods of use
EA201390428A1 (ru) Композиции и способы лечения легочной гипертензии
EA201290859A1 (ru) Лечение люпус-артрита с использованием лаквинимода
MX2013012588A (es) Inhibidores de cinasa.
EA201170753A1 (ru) Налмефена гидрохлорид дигидрат
GB2499559A (en) Treating cough and tussive attacks
WO2011014825A3 (en) Antiangiogenic small molecules and methods of use
WO2012071369A3 (en) A non-retinoid rbp4 antagonist for treatment of age-related macular degeneration and stargardt disease
CA2881554C (en) Methods for inhibiting fascin
MX2012013740A (es) Metodos para tratar trastornos resistentes al metotrexato con 10-propargil-10-deaza-aminopterina.
MX367811B (es) D-metadona para el tratamiento de síntomas psiquiátricos.
PH12014500990A1 (en) Methods for treating gout flares
AU2011322715A8 (en) Treatment of MeCP2-associated disorders
EA201690327A1 (ru) Терапевтические способы
MX342153B (es) Compuestos para el tratamiento y profilaxis de enfermedad por el virus sincitial respiratorio.
MX2010002032A (es) Uso de flibanserina para el tratamiento de sintomas vasomotores.
TR201900438T4 (tr) Prader-wıllı sendromunun tedavisinde kullanıma yönelik asillenmemiş girelin fragmentleri.
IN2014DN00123A (es)

Legal Events

Date Code Title Description
FG Grant or registration